Eli Marsden

Eli Marsden is the founding editor of Weight Loss Rankings. He spent his early career in healthcare investment banking and the past 10+ years building pharmaceutical companies — leading drug development programs that resulted in FDA approvals and named inventor on multiple patents for new therapeutics.

Eli Marsden is a pen name used to protect the editor's personal privacy. The byline is consistent across every article so readers can recognize the editorial voice; the underlying expertise (10+ years in pharmaceutical R&D, named inventor on multiple therapeutic patents, FDA approvals as program lead) is documented above and verifiable through the artifacts cited. Disclosure of the pen name is required by our editorial-standards policy and follows the same convention used by The Economist ("Bagehot"), many Reuters / Bloomberg analysts, and a number of Substack medical newsletters.

Eli is bilingual (English and Spanish) and personally edits both the English and the Spanish corpus on Weight Loss Rankings. The /es/research articles are first-party translations and adaptations, not machine-translated copies of the English versions — clinical terminology, dosing units, and regulatory references are reviewed in both languages by the same editor who shipped the English original.

Eli is not a licensed clinician. Every clinical claim on Weight Loss Rankings is sourced to FDA prescribing information, PubMed-indexed primary research, or named regulatory filings. All health content is editorially reviewed by Eli with the support of structured verification workflows; we are actively seeking a credentialed medical reviewer (MD, PharmD, NP) to join the editorial team.

Weight Loss Rankings is reader-supported via affiliate commissions on a subset of provider links. Editorial scores and rankings are produced independently of the affiliate relationships and are not for sale. The full disclosure policy is published at /disclosure and the six-dimension scoring methodology is at /methodology.

When Eli is not editing, he is still in the pharma industry — which is both a meaningful experience signal for understanding how the GLP-1 telehealth market actually works and a potential conflict of interest readers should be aware of. Any direct conflicts on a specific provider are disclosed inline on that provider's review page.